1163141-52-3

Upstream product

• 453565-90-7 3-bromo-5-(trifluoromethoxy)benzoic acid 

Downstream Products

• 1163141-54-5 isopropyl 3-isopropoxy-5-(trifluoromethoxy)benzoate 
• 1163141-91-0 ethyl 2-(7-(5-(3-hydroxy-5-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-3-yl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetate 
• 1261504-64-6 methyl 3-hydroxy-5-(trifluoromethoxy)benzoate 
• 1610450-37-7 3-(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)-5-(trifluoromethoxy)aniline 
• 1610450-35-5 tert-butyl (3-(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)-5-(trifluoromethoxy)phenyl)carbamate 
• 1610450-34-4 3-(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)-5-(trifluoromethoxy)benzoic acid 
• 1610450-32-2 methyl 3-(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)-5-(trifluoromethoxy)benzoate 
• 1610449-55-2 1-(3-isopropyl-1-(p-tolyl)-1H-pyrazol-5-yl)-3-(4-((2-((3-(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)-5-(trifluoromethoxy)phenyl)amino)pyrimidin-4-yl)oxy)naphthalen-1-yl)urea 

Relevant academic research and scientific papers

NOVEL HETEROARYL-TRIAZOLE COMPOUNDS AS PESTICIDES

The present invention relates to novel heteroaryl-triazole compounds of the general formula (I), in which the structural elements X, R1, R2, R3, R4 and R5 have the meaning given in the description, to

KINASE INHIBITORS

There are provided compounds of formula I, wherein T, A, Q, Z, G, R4, R5a, R5b and n have meanings given in the description, which compounds have antiinflammatory activity (e.g. through inhibition of one or more of members

TETRAHYDROCYCLOPENTA[B]INDOL-3-YL CARBOXYLIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS

The present invention relates to certain (1,2,4-oxadiazol-3-yl)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl carboxylic acid derivatives of Formula (Ia) and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists of the S1P1 receptor. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of S1P1 associated disorders, for example, psoriasis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, ulcerative colitis, type I diabetes, acne, microbial infections or diseases and viral infections or diseases.